MediWound Ltd.
NASDAQ:MDWDBiotechnology
-$0.09 today
- Market cap
- $175.71M
- Beta
- 0.15
- P/E (TTM)
- -7.0
- EPS (TTM)
- -$2.03
Volume 0.17M
Average 0.09M
MDWD Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
MediWound Ltd.NASDAQ: MDWD
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q1 FY2026 depreciation & amortization of $378K rose 5.6% year over year, behind the +27.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 45.2% from the prior quarter. Over 3 fiscal years it compounded at +10.4% a year.
Context
- Depreciation & amortization amounted to 10.1% of revenue in FY2025, up 2.7 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +5.6% toward the trailing-twelve-month pace of +27.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 1.71M USD
- Year-over-year change
- +15.3%
- 4-year CAGR
- +8.4%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.71M | +15.3% |
| FY2024 | 2024-12-31 | 1.48M | +13.8% |
| FY2023 | 2023-12-31 | 1.3M | +2.4% |
| FY2022 | 2022-12-31 | 1.27M | +2.7% |
| FY2021 | 2021-12-31 | 1.24M | — |
Depreciation & Amortization vs competitors
How MDWD compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +27.6% is the 2nd highest of 9, against a peer median of -16.3%.
- Depreciation & amortization amounts to 13.0% of revenue for MDWD, versus a peer median of 37.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | €3.22M EUR | -38.0% | +23.8% | 71.9% | |
| LTM Mar 2026 | $2.42M USD | +13.1% | +32.0% | 136.2% | |
| LTM Mar 2026 | $1.88M USD | -43.4% | +65.8% | 3.4% | |
| LTM Mar 2026 | $1.88M USD | +27.6% | +10.4% | 13.0% | |
| LTM Mar 2026 | $718K USD | -3878.9% | — | — | |
| LTM Mar 2026 | $369K USD | +11.1% | +13.4% | — | |
| LTM Mar 2026 | $334K USD | +5.4% | +13.8% | 1.0% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $263.36K USD | +65.0% | +17.8% | — |
| LTM Sep 2026 | $152K USD | -97.9% | — | — | |
| LTM Mar 2026 | $142.16K USD | — | — | — | |
| Peer median (excluding MDWD) | — | -16.3% | +20.8% | 37.6% | |
Competitors are the stored peer set for MDWD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (13.55M) | (19.6M) | (6.72M) | (30.22M) | (23.88M) |
| Depreciation & Amortization | 1.24M | 1.27M | 1.3M | 1.48M | 1.71M |
| Deferred Income Tax | (124K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.67M | 1.95M | 1.94M | 3.14M | 3.11M |
| Change in Working Capital | 162K | (7.24M) | 2.34M | 1.27M | 4.77M |
| Accounts Receivables | 929K | (7.58M) | 4.76M | (1.02M) | 4.88M |
| Inventory | 257K | (721K) | (906K) | 187K | (1.36M) |
| Accounts Payables | 1.72M | 414K | (594K) | 406K | 2.35M |
| Other Working Capital | (2.75M) | 645K | (928K) | 1.7M | (1.1M) |
| Other Non-Cash Items | 1.69M | 11.74M | (9.33M) | 10.71M | (236K) |
| Operating Cash Flow | (8.92M) | (11.89M) | (10.47M) | (13.62M) | (14.53M) |
| Capital Expenditures | (489K) | (555K) | (6.46M) | (6.27M) | (5.51M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | (14.04M) |
| Sales of Investments | 4M | 0 | 0 | 0 | 0 |
| Other Investing Activities | 35K | 74K | (27.86M) | (2.12M) | 0 |
| Investing Cash Flow | 3.55M | (481K) | (34.32M) | (8.4M) | (19.54M) |
| Debt Repayment | 0 | 0 | 0 | (928K) | 0 |
| Common Stock Issued | 3K | 38.38M | 24.91M | 22.17M | 31.05M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.05M) | (2.62M) | (1.99M) | (1.84M) | (1.43M) |
| Financing Cash Flow | (1.05M) | 35.76M | 22.92M | 19.39M | 29.62M |
| Effect of Forex Changes | 88K | (549K) | (160K) | (84K) | 95K |
| Net Change in Cash | (6.33M) | 22.85M | (22.03M) | (2.71M) | (4.36M) |
| Free Cash Flow | (9.41M) | (12.44M) | (16.93M) | (19.9M) | (20.04M) |
MediWound Ltd.
NASDAQ:MDWD
Intrinsic Alpha fair value
Locked
Current Price
$13.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.